A clinicopathologic study of malignancy in VCP-associated multisystem proteinopathy

Alyaa Shmara, Mari Perez-Rosendahl, Kady Murphy, Ashley Kwon, Charles Smith, Virginia Kimonis, Alyaa Shmara, Mari Perez-Rosendahl, Kady Murphy, Ashley Kwon, Charles Smith, Virginia Kimonis

Abstract

Background: Valosin containing protein (VCP) is an important protein with many vital functions mostly related to the ubiquitin-proteasome system that provides protein quality control. VCP-associated inclusion body myopathy with Paget disease of bone and frontotemporal dementia, also termed VCP disease and multisystem proteinopathy (MSP 1), is an autosomal dominant disorder caused by monoallelic variants in the VCP gene on human chromosome 9. VCP has also been strongly involved in cancer, with over-activity of VCP found in several cancers such as prostate, pancreatic, endometrial, esophageal cancers and osteosarcoma. Since MSP1 is caused by gain of function variants in the VCP gene, we hypothesized our patients would show increased risk for developing malignancies. We describe cases of 3 rare malignancies and 4 common cancers from a retrospective dataset.

Results: Upon surveying 106 families with confirmed VCP variants, we found a higher rate of rare tumors including malignant peripheral nerve sheath tumor, anaplastic pleomorphic xanthoastrocytoma and thymoma. Some of these subjects developed cancer before displaying other classic VCP disease manifestations. We also present cases of common cancers; however, we did not find an increased rate compared to the general population. This could be related to the early mortality associated with this disease, since most patients die in their 50-60 s due to respiratory failure or cardiomyopathy which is earlier than the age at which most cancers appear.

Conclusion: This is the first study that expands the phenotype of VCP disease to potentially include rare cancers and highlights the importance of further investigation of the role of VCP in cancer development. The results of this study in VCP disease patients suggest that patients may be at an increased risk for rare tumors. A larger study will determine if patients with VCP disease develop cancer at a higher rate than the general population. If that is the case, they should be followed up more frequently and screened for recurrence and metastasis of their cancer.

Trial registration: ClinicalTrials.gov NCT01353430.

Keywords: Anaplastic pleomorphic xanthoastrocytoma; Cancer; Frontotemporal dementia; IBMPFD; Multisystem proteinopathy; Myopathy; Paget disease of bone; Peripheral nerve sheath tumor; Thymoma; VCP.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Case 1 MRI of the gluteal and pelvic area. Imaging displays a large heterogeneous enhancing mass in the posterior lateral soft tissues of the right gluteal region. Low-grade peripheral nerve sheath tumor deep to the right gluteus maximus.A- Axial B. Coronal C. Sagittal MRI. T1WI = T1 weighted image. T2WI-FS = T2 weighted, fat-suppressed. T1WI-FS + contrast = T1 weighted, fat suppressed with contrast
Fig. 2
Fig. 2
a. Histologic features of tumor resection from right gluteal region of Case 1. Section showing low-grade malignant peripheral nerve sheath tumor with hypercellular fascicles of mitotically active (arrows) spindle cells with enlarged hyperchromatic nuclei. (H&E, 200x) b. Immunohistochemistry of case 1 tumor and peripheral nerve control. The staining showed strong nuclear and cytoplasmic reactivity with mild differences between the control and the tumor
Fig. 3
Fig. 3
Case 2 brain MRI axial plane. Imaging shows lobulated heterogeneous solid left posterior frontal mass with foci of internal hemorrhage and surrounding edema causing significant mass effect and mild to moderate midline shift. A. T2WI = T2 weighted image. B. FLAIR = Fluid attenuated inversion recovery. C. SWI = Susceptibility weighted imaging
Fig. 4
Fig. 4
a Histologic features of tumor resection from left posterior frontal lobe of Case 2. Anaplastic pleomorphic xanthoastrocytoma composed of epithelioid glial cells with minimal pleomorphism (A) (H&E, 200x). Anaplastic features include less pleomorphism than is typical for low grade PXA, areas of necrosis (not pictured), and increased proliferation evidenced by Ki67 (B) (Immunohistochemistry for Ki67, 200x). b. Immunohistochemistry of case 2 tumor and frontal cortex control. The staining shows strong nuclear and cytoplasmic reactivity with mild increase in the staining in patient tumor cells
Fig. 5
Fig. 5
Chest of Case 4 at age 76 years. Chest photograph 41 years after radical mastectomy shows severe atrophy of pectoralis major muscle dating from irradiation in childhood

References

    1. Meyer H, Weihl CC. The VCP/p97 system at a glance: connecting cellular function to disease pathogenesis. J Cell Sci. 2014;127:3877.
    1. Meyer H, Bug M, Bremer S. Emerging functions of the VCP/p97 AAA-ATPase in the ubiquitin system. Nat Cell Biol. 2012;14:117–123. doi: 10.1038/ncb2407.
    1. Ju J-S, Fuentealba RA, Miller SE, Jackson E, Piwnica-Worms D, Baloh RH, Weihl CC. Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease. J Cell Biol. 2009;187:875–888. doi: 10.1083/jcb.200908115.
    1. Fessart D, Marza E, Taouji S, Delom F, Chevet E. P97/CDC-48: proteostasis control in tumor cell biology. Cancer Lett. 2013;337:26–34. doi: 10.1016/j.canlet.2013.05.030.
    1. Weihl CC, Pestronk A, Kimonis VE. Valosin-containing protein disease: inclusion body myopathy with Paget's disease of the bone and fronto-temporal dementia. Neuromuscul Disord. 2009;19:308–315. doi: 10.1016/j.nmd.2009.01.009.
    1. Al-Obeidi E, Al-Tahan S, Surampalli A, Goyal N, Wang AK, Hermann A, Omizo M, Smith C, Mozaffar T, Kimonis V. Genotype-phenotype study in patients with valosin-containing protein mutations associated with multisystem proteinopathy. Clin Genet. 2018;93:119–125. doi: 10.1111/cge.13095.
    1. Farpour F, Tehranzadeh J, Donkervoort S, Smith C, Martin B, Vanjara P, Osann K, Kimonis VE. Radiological features of Paget disease of bone associated with VCP myopathy. Skeletal Radiol. 2012;41:329–337. doi: 10.1007/s00256-011-1193-4.
    1. Kimonis V. Inclusion Body Myopathy with Paget Disease of Bone and/or Frontotemporal Dementia. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews(®). Seattle (WA): University of Washington, Seattle Copyright © 1993–2020, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved., 1993.
    1. Evangelista T, Weihl CC, Kimonis V, Lochmüller H, Clemen C, Deshaies R, Evangelista T, Eymard B, Greensmith L, Hilton-Jones D, Kimonis V, Kley R, Lochmüller H, Meyer H, Mozaffar T, Noguchi S, Ralston S, Ridha B, Udd B, Weihl C, Brumhard M, Brumhard S. 215th ENMC International Workshop VCP-related multi-system proteinopathy (IBMPFD) 13–15 November 2015, Heemskerk, The Netherlands. Neuromuscul Disord. 2016;26:535–547. doi: 10.1016/j.nmd.2016.05.017.
    1. Mehta SG, Khare M, Ramani R, Watts GD, Simon M, Osann KE, Donkervoort S, Dec E, Nalbandian A, Platt J, Pasquali M, Wang A, Mozaffar T, Smith CD, Kimonis VE. Genotype-phenotype studies of VCP-associated inclusion body myopathy with Paget disease of bone and/or frontotemporal dementia. Clin Genet. 2013;83:422–431. doi: 10.1111/cge.12000.
    1. Niwa H, Ewens CA, Tsang C, Yeung HO, Zhang X, Freemont PS. The role of the N-domain in the ATPase activity of the mammalian AAA ATPase p97/VCP. J Biol Chem. 2012;287:8561–8570. doi: 10.1074/jbc.M111.302778.
    1. Johnson JO, Mandrioli J, Benatar M, Abramzon Y, Van Deerlin VM, Trojanowski JQ, Gibbs JR, Brunetti M, Gronka S, Wuu J, Ding J, McCluskey L, Martinez-Lage M, Falcone D, Hernandez DG, Arepalli S, Chong S, Schymick JC, Rothstein J, Landi F, Wang Y-D, Calvo A, Mora G, Sabatelli M, Monsurrò MR, Battistini S, Salvi F, Spataro R, Sola P, Borghero G, Consortium I, Galassi G, Scholz SW, Taylor JP, Restagno G, Chiò A, Traynor BJ. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron. 2010;68:857–864. doi: 10.1016/j.neuron.2010.11.036.
    1. Chan N, Le C, Shieh P, Mozaffar T, Khare M, Bronstein J, Kimonis V. Valosin-containing protein mutation and Parkinson's disease. Parkinsonism Relat Disord. 2012;18:107–109. doi: 10.1016/j.parkreldis.2011.07.006.
    1. Mariani L-L, Tesson C, Charles P, Cazeneuve C, Hahn V, Youssov K, Freeman L, Grabli D, Roze E, Noël S, Peuvion J-N, Bachoud-Levi A-C, Brice A, Stevanin G, Durr A. Expanding the spectrum of genes involved in huntington disease using a combined clinical and genetic approach. JAMA Neurol. 2016;73:1105–1114. doi: 10.1001/jamaneurol.2016.2215.
    1. Gonzalez MA, Feely SM, Speziani F, Strickland AV, Danzi M, Bacon C, Lee Y, Chou T-F, Blanton SH, Weihl CC, Zuchner S, Shy ME. A novel mutation in VCP causes charcot-marie-tooth type 2 disease. Brain J Neurol. 2014;137:2897–2902. doi: 10.1093/brain/awu224.
    1. Valle CW, Min T, Bodas M, Mazur S, Begum S, Tang D, Vij N. Critical role of VCP/p97 in the pathogenesis and progression of non-small cell lung carcinoma. PLoS ONE. 2011;6:e29073. doi: 10.1371/journal.pone.0029073.
    1. Duscharla D, Reddy Kami Reddy K, Dasari C, Bhukya S, Ummanni R. Interleukin-6 induced overexpression of valosin-containing protein (VCP)/p97 is associated with androgen-independent prostate cancer (AIPC) progression. J Cell Physiopl. 2018;233:7148–7164. doi: 10.1002/jcp.26639.
    1. Long XH, Zhang ZH, Liu ZL, Huang SH, Luo QF. Inhibiting valosin-containing protein suppresses osteosarcoma cell metastasis via AKT/nuclear factor of kappa B signaling pathway in vitro. Indian J Pathol Microbiol. 2013;56:190–195. doi: 10.4103/0377-4929.120358.
    1. Acs K, Luijsterburg MS, Ackermann L, Salomons FA, Hoppe T, Dantuma NP. The AAA-ATPase VCP/p97 promotes 53BP1 recruitment by removing L3MBTL1 from DNA double-strand breaks. Nat Struct Mol Biol. 2011;18:1345–1350. doi: 10.1038/nsmb.2188.
    1. van den Boom J, Wolf M, Weimann L, Schulze N, Li F, Kaschani F, Riemer A, Zierhut C, Kaiser M, Iliakis G, Funabiki H, Meyer H. VCP/p97 extracts sterically trapped Ku70/80 rings from DNA in double-strand break repair. Mol Cell. 2016;64:189–198. doi: 10.1016/j.molcel.2016.08.037.
    1. Franz A, Orth M, Pirson PA, Sonneville R, Blow JJ, Gartner A, Stemmann O, Hoppe T. CDC-48/p97 coordinates CDT-1 degradation with GINS chromatin dissociation to ensure faithful DNA replication. Mol Cell. 2011;44:85–96. doi: 10.1016/j.molcel.2011.08.028.
    1. Raman M, Havens CG, Walter JC, Harper JW. A genome-wide screen identifies p97 as an essential regulator of DNA damage-dependent CDT1 destruction. Mol Cell. 2011;44:72–84. doi: 10.1016/j.molcel.2011.06.036.
    1. Zhu C, Rogers A, Asleh K, Won J, Gao D, Leung S, Li S, Vij KR, Zhu J, Held JM, You Z, Nielsen TO, Shao J. Phospho-Ser(784)-VCP is required for DNA damage response and is associated with poor prognosis of chemotherapy-treated breast cancer. Cell Rep. 2020;31:107745. doi: 10.1016/j.celrep.2020.107745.
    1. Livingstone M, Ruan H, Weiner J, Clauser KR, Strack P, Jin S, Williams A, Greulich H, Gardner J, Venere M, Mochan TA, DiTullio RA, Jr, Moravcevic K, Gorgoulis VG, Burkhardt A, Halazonetis TD. Valosin-containing protein phosphorylation at Ser784 in response to DNA damage. Can Res. 2005;65:7533–7540. doi: 10.1158/0008-5472.CAN-04-3729.
    1. Daroszewska A, Ralston SH. Mechanisms of disease: genetics of Paget's disease of bone and related disorders. Nat Clin Pract Rheumatol. 2006;2:270–277. doi: 10.1038/ncprheum0172.
    1. Ralston SH, Taylor JP. Rare inherited forms of paget's disease and related syndromes. Calcif Tissue Int. 2019;104:501–516. doi: 10.1007/s00223-019-00520-5.
    1. Asai T, Tomita Y, Nakatsuka S, Hoshida Y, Myoui A, Yoshikawa H, Aozasa K. VCP (p97) regulates NFkappaB signaling pathway, which is important for metastasis of osteosarcoma cell line. Jpn J Cancer Res Gann. 2002;93:296–304. doi: 10.1111/j.1349-7006.2002.tb02172.x.
    1. Custer SK, Neumann M, Lu H, Wright AC, Taylor JP. Transgenic mice expressing mutant forms VCP/p97 recapitulate the full spectrum of IBMPFD including degeneration in muscle, brain and bone. Hum Mol Genet. 2010;19:1741–1755. doi: 10.1093/hmg/ddq050.
    1. Parzych K, Saavedra-García P, Valbuena GN, Al-Sadah HA, Robinson ME, Penfold L, Kuzeva DM, Ruiz-Tellez A, Loaiza S, Holzmann V, Caputo V, Johnson DC, Kaiser MF, Karadimitris A, Lam EWF, Chevet E, Feldhahn N, Keun HC, Auner HW. The coordinated action of VCP/p97 and GCN2 regulates cancer cell metabolism and proteostasis during nutrient limitation. Oncogene. 2019;38:3216–3231. doi: 10.1038/s41388-018-0651-z.
    1. Wu J, Patmore DM, Jousma E, Eaves DW, Breving K, Patel AV, Schwartz EB, Fuchs JR, Cripe TP, Stemmer-Rachamimov AO, Ratner N. EGFR-STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors. Oncogene. 2014;33:173–180. doi: 10.1038/onc.2012.579.
    1. Smoll NR, Hamilton B. Incidence and relative survival of anaplastic astrocytomas. Neuro Oncol. 2014;16(10):1400–1407. doi: 10.1093/neuonc/nou053.
    1. Engels EA. Epidemiology of thymoma and associated malignancies. J Thorac Oncol. 2010;5(10 Suppl 4):S260–S265. doi: 10.1097/JTO.0b013e3181f1f62d.
    1. U.S. Breast Cancer Statistics [Internet]. . 2021 [cited 2021Oct17]. Available from:
    1. Cancer of the pancreas - cancer stat facts [Internet]. SEER. [cited 2021Oct17]. Available from:
    1. Diet and cancer report [Internet]. WCRF International. 2021 [cited 2021Oct17]. Available from:
    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi: 10.3322/caac.21492.
    1. Kimonis VE, Kovach MJ, Waggoner B, Leal S, Salam A, Rimer L, Davis K, Khardori R, Gelber D. Clinical and molecular studies in a unique family with autosomal dominant limb-girdle muscular dystrophy and Paget disease of bone. Genet Med Offi J Am Coll Med Genet. 2000;2:232–241.
    1. Kovach MJ, Waggoner B, Leal SM, Gelber D, Khardori R, Levenstien MA, Shanks CA, Gregg G, Al-Lozi MT, Miller T, Rakowicz W, Lopate G, Florence J, Glosser G, Simmons Z, Morris JC, Whyte MP, Pestronk A, Kimonis VE. Clinical delineation and localization to chromosome 9p13.3-p12 of a unique dominant disorder in four families: hereditary inclusion body myopathy, Paget disease of bone, and frontotemporal dementia. Mol Genet Metab. 2001;74:458–475. doi: 10.1006/mgme.2001.3256.
    1. Lukas RV, Merrell RT. BRAF inhibition with concomitant tumor treating fields for a multiply progressive pleomorphic xanthoastrocytoma. CNS Oncol. 2018;7:CNS10–CNS. doi: 10.2217/cns-2017-0032.
    1. Riedel RF, Burfeind WR., Jr Thymoma: benign appearance, malignant potential. Oncologist. 2006;11:887–894. doi: 10.1634/theoncologist.11-8-887.
    1. Surampalli ANA, Donkervoort S, Khare M, Wang AK, et al. A clinicopathologic case report of a female with valosin-containing protein (VCP) gene mutation related disease. Int J Neurodegener Disord. 2018;1:1–006.
    1. Watts GDJ, Wymer J, Kovach MJ, Mehta SG, Mumm S, Darvish D, Pestronk A, Whyte MP, Kimonis VE. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet. 2004;36:377–381. doi: 10.1038/ng1332.
    1. Haubenberger D, Bittner RE, Rauch-Shorny S, Zimprich F, Mannhalter C, Wagner L, Mineva I, Vass K, Auff E, Zimprich A. Inclusion body myopathy and Paget disease is linked to a novel mutation in the VCP gene. Neurology. 2005;65:1304–1305. doi: 10.1212/01.wnl.0000180407.15369.92.
    1. Kimonis VE, Mehta SG, Fulchiero EC, Thomasova D, Pasquali M, Boycott K, Neilan EG, Kartashov A, Forman MS, Tucker S, Kimonis K, Mumm S, Whyte MP, Smith CD, Watts GD. Clinical studies in familial VCP myopathy associated with Paget disease of bone and frontotemporal dementia. Am J Med Genet A. 2008;146A:745–757. doi: 10.1002/ajmg.a.31862.
    1. Farid M, Demicco EG, Garcia R, Ahn L, Merola PR, Cioffi A, Maki RG. Malignant peripheral nerve sheath tumors. Oncologist. 2014;19:193–201. doi: 10.1634/theoncologist.2013-0328.
    1. Watson KL, Al Sannaa GA, Kivlin CM, Ingram DR, Landers SM, Roland CL, Cormier JN, Hunt KK, Feig BW, Ashleigh Guadagnolo B, Bishop AJ, Wang W-L, Slopis JM, McCutcheon IE, Lazar AJ, Torres KE. Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors. J Neurosurg. 2017;126:319–329. doi: 10.3171/2015.12.JNS152443.
    1. Fu Q, Jiang Y, Zhang D, Liu X, Guo J, Zhao J. Valosin-containing protein (VCP) promotes the growth, invasion, and metastasis of colorectal cancer through activation of STAT3 signaling. Mol Cell Biochem. 2016;418:189–198. doi: 10.1007/s11010-016-2746-6.
    1. Ida CM, Rodriguez FJ, Burger PC, Caron AA, Jenkins SM, Spears GM, Aranguren DL, Lachance DH, Giannini C. Pleomorphic xanthoastrocytoma: natural history and long-term follow-Up. Brain Pathol. 2015;25:575–586. doi: 10.1111/bpa.12217.
    1. Phillips JJ, Gong H, Chen K, Joseph NM, van Ziffle J, Bastian BC, Grenert JP, Kline CN, Mueller S, Banerjee A, Nicolaides T, Gupta N, Berger MS, Lee HS, Pekmezci M, Tihan T, Bollen AW, Perry A, Shieh JTC, Solomon DA. The genetic landscape of anaplastic pleomorphic xanthoastrocytoma. Brain Pathol. 2019;29:85–96. doi: 10.1111/bpa.12639.
    1. Aladhraei M, Kassem Al-Thobhani A, Poungvarin N, Suwannalert P. Association of XPO1 Overexpression with NF-κB and Ki67 in Colorectal Cancer. Asian Pac J Cancer Prev. 2019;20(12):3747–3754. doi: 10.31557/APJCP.2019.20.12.3747.
    1. Meteoglu I, Erdogdu IH, Tuncyurek P, Coskun A, Culhaci N, Erkus M, Barutca S. Nuclear factor Kappa B, matrix metalloproteinase-1, p53, and Ki-67 expressions in the primary tumors and the lymph node metastases of colorectal cancer cases. Gastroenterol Res Pract. 2015;2015:945392. doi: 10.1155/2015/945392.
    1. Jackson MW, Palma DA, Camidge DR, Jones BL, Robin TP, Sher DJ, Koshy M, Kavanagh BD, Gaspar LE, Rusthoven CG. The impact of postoperative radiotherapy for thymoma and thymic carcinoma. J Thorac Oncol. 2017;12:734–744. doi: 10.1016/j.jtho.2017.01.002.
    1. Petrini I, Meltzer PS, Kim I-K, Lucchi M, Park K-S, Fontanini G, Gao J, Zucali PA, Calabrese F, Favaretto A, Rea F, Rodriguez-Canales J, Walker RL, Pineda M, Zhu YJ, Lau C, Killian KJ, Bilke S, Voeller D, Dakshanamurthy S, Wang Y, Giaccone G. A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. Nat Genet. 2014;46:844–849. doi: 10.1038/ng.3016.
    1. Enkner F, Pichlhöfer B, Zaharie AT, Krunic M, Holper TM, Janik S, Moser B, Schlangen K, Neudert B, Walter K, Migschitz B, Müllauer L. Molecular profiling of thymoma and thymic carcinoma: genetic differences and potential novel therapeutic targets. Pathol Oncol Res. 2017;23:551–564. doi: 10.1007/s12253-016-0144-8.
    1. Moskowitz CS, Chou JF, Wolden SL, Bernstein JL, Malhotra J, Novetsky Friedman D, Mubdi NZ, Leisenring WM, Stovall M, Hammond S, Smith SA, Henderson TO, Boice JD, Hudson MM, Diller LR, Bhatia S, Kenney LB, Neglia JP, Begg CB, Robison LL, Oeffinger KC. Breast cancer after chest radiation therapy for childhood cancer. J Clin Oncol. 2014;32:2217–2223. doi: 10.1200/JCO.2013.54.4601.
    1. Cui Y, Niu M, Zhang X, Zhong Z, Wang J, Pang D. High expression of valosin-containing protein predicts poor prognosis in patients with breast carcinoma. Tumor Biology. 2015;36:9919–9927. doi: 10.1007/s13277-015-3748-9.
    1. Magnaghi P, D'Alessio R, Valsasina B, Avanzi N, Rizzi S, Asa D, Gasparri F, Cozzi L, Cucchi U, Orrenius C, Polucci P, Ballinari D, Perrera C, Leone A, Cervi G, Casale E, Xiao Y, Wong C, Anderson DJ, Galvani A, Donati D, O'Brien T, Jackson PK, Isacchi A. Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death. Nat Chem Biol. 2013;9:548–556. doi: 10.1038/nchembio.1313.
    1. Anderson DJ, Le Moigne R, Djakovic S, Kumar B, Rice J, Wong S, Wang J, Yao B, Valle E, Kiss von Soly S, Madriaga A, Soriano F, Menon M-K, Wu ZY, Kampmann M, Chen Y, Weissman JS, Aftab BT, Yakes FM, Shawver L, Zhou H-J, Wustrow D, Rolfe M. Targeting the AAA ATPase p97 as an approach to treat cancer through disruption of protein homeostasis. Cancer Cell. 2015;28:653–65. doi: 10.1016/j.ccell.2015.10.002.
    1. Bastola P, Neums L, Schoenen FJ, Chien J. VCP inhibitors induce endoplasmic reticulum stress, cause cell cycle arrest, trigger caspase-mediated cell death and synergistically kill ovarian cancer cells in combination with Salubrinal. Mol Oncol. 2016;10:1559–1574. doi: 10.1016/j.molonc.2016.09.005.
    1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–767. doi: 10.1016/0092-8674(90)90186-I.
    1. Bayraktar O, Oral O, Kocaturk NM, Akkoc Y, Eberhart K, Kosar A, Gozuacik D. IBMPFD disease-causing mutant VCP/p97 proteins are targets of autophagic-lysosomal degradation. PLoS ONE. 2016;11:e0164864-e. doi: 10.1371/journal.pone.0164864.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner